In the preceding three months, 6 analysts have released ratings for Xencor (NASDAQ:XNCR), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 3 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.33, along with a high estimate of $50.00 and a low estimate of $24.00. Experiencing a 21.84% decline, the current average is now lower than the previous average price target of $45.20.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Xencor among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Kaveri Pohlman | BTIG | Lowers | Buy | $38.00 | $56.00 |
| Edward Tenthoff | Piper Sandler | Lowers | Neutral | $24.00 | $37.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $32.00 | - |
| Etzer Darout | BMO Capital | Lowers | Outperform | $34.00 | $38.00 |
| David Nierengarten | Wedbush | Lowers | Outperform | $34.00 | $36.00 |
| Mara Goldstein | Mizuho | Lowers | Buy | $50.00 | $59.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xencor. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Xencor compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Xencor's stock. This examination reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Xencor's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Xencor analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Xencor
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Breaking Down Xencor's Financial Performance
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Xencor's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 106.8%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Xencor's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -42.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Xencor's ROE stands out, surpassing industry averages. With an impressive ROE of -2.86%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Xencor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: Xencor's debt-to-equity ratio is below the industry average. With a ratio of 0.12, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.